Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection
Journal Title: Viral Hepatitis Journal - Year 2020, Vol 26, Issue 2
Abstract
Objectives: This study aimed to investigate the effect of treatment with direct-acting antivirals (DAAs) on the virological response and on the some parameters used to evaluate liver function in cases with chronic liver disease due to hepatitis C virus (HCV) genotype 1b. Materials and Methods:This study included cases who were treated with DAAs after HCV genotype 1b infection. HCV-RNA levels and biochemical and hematological parameters measured at the beginning of treatment, 12th week and 52th week after the treatment were transferred to the SPSS statistics software. model for end-stage liver disease (MELD) and Child-Pugh scores were also calculated and added to these data. Results: The study group consisted of a total of 102 patients, including 33 (32%) males and 69 (68%) females. Compensated cirrhosis was detected in 26.5% of the patients (n=27). There was a significant change in serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and alpha-fetoprotein (AFP) parameters in patients with compensated cirrhosis after treatment, and total bilirubin, hemoglobin, ALT, AST, GGT, ALP and AFP parameters in the group without cirrhosis (p<0.05). Only a significant decrease was observed in the MELD score of the patients with compensated cirrhosis (p=0.007). Conclusion: The ombitasvir/paritaprevir/ritonavir+dasabuvir and ledipasvir/sofosbuvir regimens are very effective and safe in the treatment of patients who develop chronic liver disease and compensated liver cirrhosis after HCV genotype 1b infection.
Authors and Affiliations
Mustafa Doğan, Birol Topçu, Rıtvan Karaali, İlknur Erdem
Keywords
Related Articles
- EP ID EP688797
- DOI 10.4274/vhd.galenos.2020.2020.0016
- Views 115
- Downloads 0
Examination of Mutations in the HBsAg and Polymerase Genes Induced by Pegylated Interferon Alpha and Oral Antivirals Used in the Treatment of Chronic Hepatitis B
Objectives: The Hepatitis B Virus is a virus having high mutation frequency due to having a high replication capacity and not having error correction capability in reverse transcription.It is aimed to examine the mutatio...
Hepatitis and HIV Seropositivity among Healthcare Workers at Elazığ Oral and Dental Healthcare Center
Objectives: In this study, we aimed to explore the prevalence of hepatitis B virus (HBV), HCV and Human immunodeficiency virus (HIV) infection, and anti-HBs and anti-HAV-IgG seropositivity among dentists, supporting heal...
Effect of Hepatitis C Infection and Its Clearance on the Frequency of Coronary Artery Disease in Diabetics
Objectives: Chronic hepatitis C (CHC) infection considered to be associated with an increased risk of coronary artery disease (CAD). However, there is not enough data concerning this association in diabetics. Thus, this...
The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients. Material...
Direct-acting Antiviral Therapy for Mixed Genotype Chronic Hepatitis C Infection
Objectives: Literature data concerning the outcomes of direct acting antiviral (DAA) therapy in mixed genotype hepatitis C virus (HCV) infections are very limited, and the incidence of mixed HCV infection in Turkey is un...